for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Granules India Ltd

GRAN.NS

Latest Trade

97.00INR

Change

-0.25(-0.26%)

Volume

190,761

Today's Range

95.00

 - 

97.25

52 Week Range

79.15

 - 

120.40

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
97.25
Open
97.25
Volume
190,761
3M AVG Volume
11.90
Today's High
97.25
Today's Low
95.00
52 Week High
120.40
52 Week Low
79.15
Shares Out (MIL)
254.25
Market Cap (MIL)
24,725.58
Forward P/E
8.42
Dividend (Yield %)
1.03

Next Event

Q2 2020 Granules India Ltd Earnings Call

Latest Developments

More

Granules India Receives FDA EIR For Hyderabad Plant With One Observation

Ajinomoto Bio-Pharma Services Acquires Remaining Interest In Granules Omnichem Joint Venture In India

Granules India June Qtr Consol Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Granules India Ltd

Granules India Limited is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The Company's business operations include three areas: core business, emerging business, and contract research and manufacturing services (CRAMS). Its products in Core business include Paracetamol, Ibuprofen, Guaifenesin and Metformin. The Company operates a healthcare division, Granules Consumer Healthcare (GCH). The Company, through an acquisition, has access to over 10 APIs, as well as intermediates in therapeutic categories, such as anti-histaminic, antihypertensive and anti-convulsants. The Company's PFI products include Compresso PAP 97 S, Compresso PAP 90 CPC and Paracetamol Caffeine Combo 77.4. The Company's FDs include Paracetamol/Acetaminophen, and Acetaminophen and Methocarbamol.

Industry

Biotechnology & Drugs

Contact Info

Second Floor

Block III, My Home Hub, Madhapur

+91.40.66760000

http://www.granulesindia.com/

Executive Leadership

K. Ganesh

Chief Financial Officer

Chaitanya Tummala

Compliance Officer, Company Secretary

Chigurupati Krishna Prasad

Chairman of the Board, Managing Director

Harsha Chigurupati

Executive Director

Uma Devi Chigurupati

Non-Independent Executive Director

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

14.1K

2018

16.8K

2019

22.8K

2020(E)

26.1K
EPS (INR)

2017

7.480

2018

5.470

2019

9.280

2020(E)

11.552
Price To Earnings (TTM)
9.26
Price To Sales (TTM)
1.02
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
6.55
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Granules India Gets One Form 483 Observation For Jeedimeetla Facility

* GAGILLAPUR, JEEDIMETLA FACILITIES COMPLETED U.S. FDA INSPECTION; NO 483 OBSERVATION FOR GAGILLAPUR; 1 OBSERVATION FOR JEEDIMEETLA Source text - http://bit.ly/2G5IloH Further company coverage:

BRIEF-Granules India Says U.S. FDA Approves ANDA For Metformin Extended Release Tablets

* USFDA APPROVED ANDA FILED BY CO FOR METFORMIN EXTENDED RELEASE (ER) TABLETS 500 MG AND 750 MG

BRIEF-Granules India Says U.S. FDA Issued EIR For Unit's Facility In Virginia

* SAYS U.S. FDA ISSUED EIR FOR GRANULES PHARMA FACILITY IN CHANTILLY, VIRGINIA

BRIEF-Granules India Dec Qtr Consol Profit Falls

* DEC QUARTER CONSOL NET PROFIT 350.2 MILLION RUPEES VERSUS 390.6 MILLION RUPEES YEAR AGO

BRIEF-Granules India's Virginia Unit Completes U.S. FDA Audit With 1 Observation

* SAYS GRANULES PHARMACEUTICALS COMPLETES U.S. FDA INSPECTION WITH 1 OBSERVATION Source text: http://bit.ly/2AK3Fdu Further company coverage:

BRIEF-Granules India Sept-qtr consol profit falls

* Sept quarter consol net profit 403.4 million rupees versus profit 408.2 million rupees year ago

BRIEF-Granules India gets USFDA approval for Prasugrel tablet

* Says receipt of approval from US FDA for ANDA filed by USpharma Windlas, LLC

BRIEF-Granules India gets shareholders' nod for rise in investment limit of foreign institutional, portfolio investors

* Gets shareholders' nod for increase in investment limit of foreign institutional and foreign portfolio investors Source text -http://bit.ly/2x0Am7O Further company coverage:

BRIEF-Granules India approves QIP issue price of 121.25 rupees/shr

* Says board approves QIP issue price of 121.25 rupees/ shr Source text: http://bit.ly/2hsRxUZ Further company coverage:

BRIEF-Granules India seeks shareholders' nod for increase in investment limits of FIIs/FPIs

* Seeks shareholders' nod for increase in investment limits of foreign institutional investors and foreign portfolio investors Source text - http://bit.ly/2x4qz03 Further company coverage:

BRIEF-Granules India declares dividend of 0.25 rupees per share

* Declared dividend of 0.25 rupees per share Source text for Eikon: Further company coverage:

BRIEF-Granules India gets members' nod for further issue of securities via QIP

* Gets members' nod for further issue of securities via QIP Source text - (http://bit.ly/2rltnU3) Further company coverage:

RPT-BRIEF-Granules India seeks members' nod for issue of securities via QIP worth 5 bln rupees (May 17)

* Seeks members' nod for issue of securities via QIP worth 5 billion rupees Source text for Eikon: http://bit.ly/2rcPTxN Further company coverage:

BRIEF-Granules India seeks members' nod for issue of securities via QIP worth 5 bln rupees

* Seeks members' nod for issue of securities via QIP worth 5 billion rupees Source text for Eikon: Further company coverage:

BRIEF-Granules India March-qtr consol profit rises

* March quarter consol net profit 456.7 million rupees versus profit 329.9 million rupees year ago

BRIEF-Granules India Gagillapur unit completes INFARMED re-inspection

* Says Granules India's Gagillapur facility (Telangana) completed INFARMED re-inspection Source text: http://bit.ly/2kntrM5 Further company coverage:

BRIEF-Granules India's Gagillapur unit completes inspection by INFARMED with 11 observations

* Says co's Gagillapur facility completed inspection by infarmed, Portugal

BRIEF-Granules India Sept-qtr consol profit rises

* Sept quarter consol net profit 408.2 million rupees versus profit 322.7 million rupees year ago

BRIEF-Granules India's Gagillapur facility successfully completes USFDA inspection

* Granules India's Gagillapur facility successfully completed us fda inspection Source text: http://bit.ly/2dUN37Z Further company coverage: (Bengaluru newsroom)

BRIEF-Granules India gets US FDA nod for Ibuprofen 200 mg tablets

* Granules India says Granules India Limited, received US FDA approval for Ibuprofen 200 mg tablets Source text: http://bit.ly/2dMq1QR Further company coverage: (Bengaluru newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up